Cholesterol Management Prescribed by UK Doctors

Hypercholesterolaemia is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), which remains the leading cause of death in the UK, accounting for over 160,000 deaths annually.

Total cholesterol above 5.0 mmol/L is found in roughly 55% of UK adults, yet many remain unaware because elevated lipids produce no symptoms until a vascular event occurs.

Low-density lipoprotein (LDL) is the primary atherogenic particle. Each 1.

0 mmol/L reduction in LDL cholesterol cuts major cardiovascular events by approximately 22%, according to the Cholesterol Treatment Trialists' Collaboration meta-analysis of 170,000 participants across 26 trials.

This dose-response relationship holds regardless of starting LDL level.

Familial hypercholesterolaemia (FH) affects 1 in 250 people in the UK — around 270,000 individuals — yet fewer than 10% have been identified and treated.

Heterozygous FH produces LDL levels of 5-10 mmol/L from birth, leading to premature coronary disease in 50% of untreated men by age 50.

Risk assessment in UK primary care follows the QRISK3 algorithm, which estimates 10-year cardiovascular risk using factors including age, sex, ethnicity, systolic blood pressure, total-to-HDL cholesterol ratio, smoking status, diabetes, CKD, atrial fibrillation, and rheumatoid arthritis.

Key lipid thresholds to understand:

• Total cholesterol target: below 5.0 mmol/L for general population
• LDL cholesterol: below 3.0 mmol/L for primary prevention, below 2.0 mmol/L for secondary prevention
• HDL cholesterol: above 1.0 mmol/L in men, above 1.2 mmol/L in women
• Triglycerides: below 1.7 mmol/L fasting
• Non-HDL cholesterol (total minus HDL): below 4.0 mmol/L, increasingly used as a primary target

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, triggering upregulation of LDL receptors on liver cells and increased clearance of LDL from the bloodstream.

They remain the cornerstone of lipid-lowering therapy per NICE CG181 and the 2019 ESC/EAS dyslipidaemia guidelines.

Atorvastatin 20 mg is the NICE-recommended first-line agent for primary prevention when QRISK3 exceeds 10%. It lowers LDL by approximately 43% and costs as little as £0.15 per day.

For secondary prevention (established ASCVD), atorvastatin 80 mg is standard, achieving LDL reductions of 50-55%.

Rosuvastatin is the most potent statin available. At 10 mg it reduces LDL by 46%, and at 20 mg by approximately 52%.

The JUPITER trial demonstrated a 44% reduction in major cardiovascular events with rosuvastatin 20 mg in patients with elevated CRP but normal LDL.

It is renally cleared, making it an alternative when hepatic concerns arise.

Simvastatin was historically dominant but has largely been superseded.

Its 40 mg dose achieves only 37% LDL reduction, and the 80 mg dose carries an unacceptable myopathy risk (1 in 10,000 per year), prompting the MHRA to advise against its routine use.

Prescribing protocol at Dr. Presc follows NICE guidance:

• Baseline lipid profile, liver function (ALT), renal function, HbA1c, and thyroid function
• Repeat lipid profile at 3 months to assess response
• Liver function check at 3 and 12 months; discontinue if ALT exceeds 3x upper limit
• Dose titration if LDL target not achieved at initial dose
• Addition of ezetimibe 10 mg if maximum-tolerated statin fails to reach target (adds 15-20% further LDL reduction)

Statin-related adverse effects are a frequent cause of discontinuation, yet true pharmacological intolerance is far less common than perceived intolerance.

The SAMSON trial, a landmark n-of-1 study published in the New England Journal of Medicine, found that 90% of statin side effects were reproduced equally by placebo, demonstrating a strong nocebo component.

Myalgia (muscle aching without CK elevation) is reported by 5-10% of statin users. It typically appears within the first 4-12 weeks and affects the proximal limb muscles.

• Check creatine kinase (CK): if above 5x upper limit of normal, stop the statin immediately
• If CK is normal, trial a drug holiday for 2-4 weeks to confirm the association
• Re-challenge with the same statin at a lower dose, or switch to an alternative
• Rosuvastatin and pravastatin have lower lipophilicity and may be better tolerated
• Alternate-day dosing of atorvastatin or rosuvastatin (both have long half-lives) maintains 70-80% of LDL-lowering effect

Hepatotoxicity is rare. Transaminase elevations above 3x normal occur in under 1% of patients and are dose-dependent.

Statins are not contraindicated in non-alcoholic fatty liver disease; in fact, evidence suggests they may slow fibrosis progression.

Diabetes risk increases by approximately 9-12% with statin therapy, primarily in patients already at high metabolic risk.

The cardiovascular benefit far outweighs this risk: for every case of diabetes caused, statins prevent roughly 5 cardiovascular events.

Other reported effects and their clinical significance:

• Cognitive complaints: no causal link established in systematic reviews
• Tendon disorders: very rare, usually resolve on discontinuation
• Haemorrhagic stroke: marginal increase (0.05% absolute) offset by much larger reduction in ischaemic stroke

Lifestyle intervention forms the foundation of cardiovascular risk management and can achieve clinically meaningful LDL reductions of 10-20% without medication.

NICE CG181 mandates that all patients receive lifestyle advice before and alongside statin therapy.

Dietary fat composition matters more than total fat intake. Replacing saturated fat (butter, cheese, fatty meat) with unsaturated fat (olive oil, nuts, oily fish) reduces LDL by 8-12%.

The PREDIMED trial showed that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced cardiovascular events by 30% compared with a reduced-fat diet.

Specific dietary interventions with quantified LDL effects:

• Plant stanols/sterols (2 g/day): 10-15% LDL reduction
• Soluble fibre (oats, barley, psyllium, 7-13 g/day): 5-10% LDL reduction
• Soy protein (25 g/day replacing animal protein): 3-5% LDL reduction
• Almonds (42 g/day): 5-7% LDL reduction in the Portfolio Diet studies

Physical activity raises HDL cholesterol by 3-8% and lowers triglycerides by 10-20%. The benefit requires at least 150 minutes per week of moderate-intensity aerobic exercise.

Resistance training adds modest HDL benefit when combined with aerobic work.

Smoking cessation raises HDL by 5-10% within 12 months and halves cardiovascular risk within 2-5 years. This is independent of any lipid-lowering medication.

Alcohol in moderation (under 14 units per week) has minimal effect on LDL but raises HDL and triglycerides.

Heavy drinking substantially increases triglycerides and should be addressed as a priority in hypertriglyceridaemic patients.

Weight loss of 5-10% body weight reduces LDL by 5-8%, raises HDL by 2-3%, and cuts triglycerides by 15-20%.

Visceral adiposity is the key driver, making waist circumference (target below 94 cm for men, below 80 cm for women) a useful monitoring metric.

Cholesterol management requires ongoing monitoring and, in certain clinical scenarios, prompt medical evaluation beyond routine online consultations.

Suspected familial hypercholesterolaemia should be investigated whenever total cholesterol exceeds 7.5 mmol/L or LDL exceeds 4.

9 mmol/L, particularly with a family history of premature coronary disease (first-degree relative affected before age 55 in men or 65 in women).

The Simon Broome or Dutch Lipid Network criteria guide formal diagnosis. NICE CG71 recommends cascade screening of first-degree relatives.

Severe hypertriglyceridaemia (above 10 mmol/L) carries a significant risk of acute pancreatitis and warrants urgent specialist referral.

Fibrates (bezafibrate, fenofibrate) and omega-3 fatty acid concentrates may be indicated alongside dietary restriction of refined carbohydrates and alcohol.

Scenarios requiring face-to-face GP or specialist review:

• New-onset chest pain, transient ischaemic attack, or peripheral arterial symptoms
• CK elevation above 5x upper limit of normal with muscle symptoms
• Persistent ALT elevation above 3x upper limit despite dose reduction
• Failure to achieve 40% LDL reduction on maximum-tolerated statin plus ezetimibe
• Pregnancy or planned pregnancy (statins are contraindicated; stop 3 months before conception)
• Age under 40 with elevated lipids (higher probability of genetic cause)

Patients with established cardiovascular disease who fail to reach an LDL target of 2.

0 mmol/L may be candidates for PCSK9 inhibitors (alirocumab, evolocumab), which reduce LDL by a further 50-60%. These are commissioned through specialist lipid clinics under NICE TA394 and TA393.

Regular monitoring ensures treatment remains effective: repeat lipid profiles at 3 months post-initiation, then annually.

Annual QRISK3 reassessment captures any changes in risk profile that might warrant treatment escalation.